- Home
- APMD vs CHY Comparison
APMD vs CHY Comparison
Compare APMD & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | APMD | CHY |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.5M | 960.4M |
| IPO Year | 2026 | 2003 |
Fundamental Metrics
Financial Performance| Metric | APMD | CHY |
|---|---|---|
| Price | $18.65 | $11.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $50.33 | N/A |
| AVG Volume (30 Days) | ★ 380.6K | 247.3K |
| Earning Date | 11-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.11% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $136.17 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.43 | $10.41 |
| 52 Week High | $35.29 | $13.91 |
Technical Indicators
Market Signals| Indicator | APMD | CHY |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 35.49 |
| Support Level | $17.38 | $10.41 |
| Resistance Level | $20.00 | $11.95 |
| Average True Range (ATR) | 1.62 | 0.27 |
| MACD | 0.22 | -0.03 |
| Stochastic Oscillator | 41.02 | 15.23 |
Price Performance
Historical ComparisonAbout APMD Apnimed Inc. Common Stock
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.